Webinar Cell culture media manufacturing, outsourcing and the pandemic: an essential toolkit
On October 1, 2020, two scientists from Thermo Fisher Scientific, Chad Schwartz, Senior Global Product Manager, and Eric Nalbach, Director of Product Management, participated in a BioProcess International—Ask the Expert webinar. Eric and Chad outline the impact of SARS-CoV-2 on global supply chains and the importance of facility redundancy and rigorous site equivalency in providing quality, particularly in times of crisis. Global supply networks are facing increasing pressure. Typically, supply chain administrators and demand planners would strategically plan for the year ahead. But with so many new vaccines and therapies working their way through the supply chain, we are in a wholly unpredictable period. Demand for products such as cell culture media and supplements, raw materials, and single-use products has risen sharply and supply chains are becoming more complex and costly to maintain. All of these pressures support partnering with established suppliers that maintain worldwide redundancy. Outsourcing your media manufacturing, or qualifying a secondary or tertiary supplier, has the potential to alleviate some of these pressures. At this time of unpredictability, having access to additional capacity is paramount to risk mitigation. Considering the approval of multiple sites and/or vendors for media and bulk process liquids may be your best bet. In fact, strategic outsourcing may become an essential way for manufacturers to produce biologics that are related or unrelated to SARS-CoV-2 over the next few years.